Ensysce Biosciences, Inc.
ENSCNASDAQHealthcare● Active
$0.25
$-0.00(-0.43%)
Market Cap$2347288
P/E Ratio—
52W High$2.75
52W Low$0.23
Ensysce Biosciences, Inc. (ENSC) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ENSC · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($10176187.00M) | ($7.99M) | ($10.63M) | ($24.21M) | ($29.15M) |
| Depreciation & Amort. | $6533.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $668682.00M | $110723.00M | $0.88M | $1.07M | $0.12M |
| Change in Working Capital | $1.52M | ($0.85M) | ($0.95M) | $5.48M | ($1.30M) |
| Net Cash from Operations | ($7806292.00M) | ($7502700.00M) | ($10.78M) | ($17.89M) | ($8.24M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($123643.00M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | ($290.00M) | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($0.49M) | $0.61M | $6.13M | $13.91M |
| Net Cash from Financing | $8738212.00M | $9881173.00M | $8.76M | $8.77M | $20.31M |
| Free Cash Flow | |||||
| Free Cash Flow | ($7806292.00M) | ($7502700.00M) | ($10.78M) | ($17.89M) | ($8.24M) |
| FCF Margin %(computed) | — | — | -483.19% | -708.87% | -233.41% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Ensysce Biosciences, Inc. data
About Ensysce Biosciences, Inc. (ENSC) Cash Flow Statement
Ensysce Biosciences, Inc. generated operating cash flow of ($7806.29B) and free cash flow of ($7806.29B) for 2025 — a FCF margin of -154072059.45%. Capital expenditure was $0.00B.
Frequently asked questions
ENSC · 4 questionsEnsysce Biosciences, Inc. generated free cash flow of ($7806.29B) for 2025, down 4.0% year-over-year.
ENSC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10